Evidence network for deaths_(OS)

4KEYNOTE-024 (PDL1>50%), 2016 KEYNOTE-042 (PDL1>50%), 2019 KEYNOTE-042 (PDL1>20%), 2019 KEYNOTE-042 (PDL1>1%), 20192CheckMate 026 (PDL1>5%), 2016 CheckMate 026 (PDL1>1%), 20161MYSTIC (D ; PDL1>25%), 20201CheckMate 227 (NI vs C ; PDL1>1%), 20183IMpower-110 (TC3 or IC3), 2020 IMpower-110 (TC2/3 or IC2/3), 2020 IMpower-110 (TC1/2/3 or IC1/2/3), 20201MYSTIC (DT ; PDL1>25%), 20201KEYNOTE-598, 20201EMPOWER lung1 (PDL1>50%), 2021Standard of Care (SoC)pemetrexed plus platinpembrolizumab plus placebochemotherapypembrolizumab alonenivolumab alonedurvalumab alonenivolumab plus ipilimumabatezolizumab alonedurvalumab plus tremelimumabpembrolizumab plus ipilimumabcemiplimabdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)pemetrexed plus platinpembrolizumab plus placebochemotherapypembrolizumab alonenivolumab alonedurvalumab alonenivolumab plus ipilimumabatezolizumab alonedurvalumab plus tremelimumabpembrolizumab plus ipilimumabcemiplimab
Standard of Care (SoC)---NANANANANANANANANANANA
pemetrexed plus platinNA---NANANANANANANANANANA
pembrolizumab plus placeboNANA---NANANANANANANANANA
chemotherapyNANANA---NANANANANANANANA
pembrolizumab aloneNANANANA---NANANANANANANA
nivolumab aloneNANANANANA---NANANANANANA
durvalumab aloneNANANANANANA---NANANANANA
nivolumab plus ipilimumabNANANANANANANA---NANANANA
atezolizumab aloneNANANANANANANANA---NANANA
durvalumab plus tremelimumabNANANANANANANANANA---NANA
pembrolizumab plus ipilimumabNANANANANANANANANANA---NA
cemiplimabNANANANANANANANANANANA---

pathologies: 171 - treatments: 1049 result logic